Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report
Gastritis related to immunotherapy use is a less commonly reported adverse effect. With increasing use of immunotherapy agents in the management of patients with endometrial cancer, even rare adverse effects are being seen more frequently in gynecologic oncology practice. A 66-year-old with recurren...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578923000437 |
| _version_ | 1797802184616706048 |
|---|---|
| author | Nidhi Goel Monica D. Levine Laura M. Chambers Christa I. Nagel |
| author_facet | Nidhi Goel Monica D. Levine Laura M. Chambers Christa I. Nagel |
| author_sort | Nidhi Goel |
| collection | DOAJ |
| description | Gastritis related to immunotherapy use is a less commonly reported adverse effect. With increasing use of immunotherapy agents in the management of patients with endometrial cancer, even rare adverse effects are being seen more frequently in gynecologic oncology practice. A 66-year-old with recurrent mismatch repair deficient endometrial cancer was treated with single-agent pembrolizumab. She initially appeared to tolerate treatment well; however after 16 months of therapy she began to develop nausea, vomiting, and abdominal pain that resulted in 30-pound weight loss. Pembrolizumab was held out of concern for immunotherapy related toxicity. She underwent evaluation with gastroenterology including esophagogastroduodenoscopy (EGD) with biopsy that demonstrated severe lymphocytic gastritis. She was treated with IV methylprednisolone with improvement in symptoms over three days. She was then transitioned to oral prednisone at 60 mg daily with weekly taper by 10 mg, with a proton pump inhibitor (PPI) and carafate until resolution of symptoms. She subsequently had a follow up EGD with biopsy, which demonstrated resolving gastritis. She is presently doing well off of steroids with stable disease noted on her last scan after cessation of pembrolizumab. |
| first_indexed | 2024-03-13T05:01:53Z |
| format | Article |
| id | doaj.art-93be8123b9524774bc184def30479cd8 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-03-13T05:01:53Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-93be8123b9524774bc184def30479cd82023-06-17T05:19:15ZengElsevierGynecologic Oncology Reports2352-57892023-06-0147101174Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case reportNidhi Goel0Monica D. Levine1Laura M. Chambers2Christa I. Nagel3Division of Obstetrics and Gynecology, The Ohio State University Medical Center, Columbus, OH, United StatesDivision of Gynecologic Oncology, The Ohio State University Medical Center, Columbus, OH, United StatesDivision of Gynecologic Oncology, The Ohio State University Medical Center, Columbus, OH, United StatesDivision of Gynecologic Oncology, The Ohio State University Medical Center, Columbus, OH, United States; Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Medical Center, M210 Starling Loving Hall 320 W 10th Ave, Columbus, OH 43215, United States.Gastritis related to immunotherapy use is a less commonly reported adverse effect. With increasing use of immunotherapy agents in the management of patients with endometrial cancer, even rare adverse effects are being seen more frequently in gynecologic oncology practice. A 66-year-old with recurrent mismatch repair deficient endometrial cancer was treated with single-agent pembrolizumab. She initially appeared to tolerate treatment well; however after 16 months of therapy she began to develop nausea, vomiting, and abdominal pain that resulted in 30-pound weight loss. Pembrolizumab was held out of concern for immunotherapy related toxicity. She underwent evaluation with gastroenterology including esophagogastroduodenoscopy (EGD) with biopsy that demonstrated severe lymphocytic gastritis. She was treated with IV methylprednisolone with improvement in symptoms over three days. She was then transitioned to oral prednisone at 60 mg daily with weekly taper by 10 mg, with a proton pump inhibitor (PPI) and carafate until resolution of symptoms. She subsequently had a follow up EGD with biopsy, which demonstrated resolving gastritis. She is presently doing well off of steroids with stable disease noted on her last scan after cessation of pembrolizumab.http://www.sciencedirect.com/science/article/pii/S2352578923000437Immunotherapy toxicityEndometrial cancerCheckpoint inhibitor gastritis |
| spellingShingle | Nidhi Goel Monica D. Levine Laura M. Chambers Christa I. Nagel Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report Gynecologic Oncology Reports Immunotherapy toxicity Endometrial cancer Checkpoint inhibitor gastritis |
| title | Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report |
| title_full | Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report |
| title_fullStr | Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report |
| title_full_unstemmed | Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report |
| title_short | Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report |
| title_sort | gastritis as an immunotherapy related toxicity in the treatment of endometrial cancer a case report |
| topic | Immunotherapy toxicity Endometrial cancer Checkpoint inhibitor gastritis |
| url | http://www.sciencedirect.com/science/article/pii/S2352578923000437 |
| work_keys_str_mv | AT nidhigoel gastritisasanimmunotherapyrelatedtoxicityinthetreatmentofendometrialcanceracasereport AT monicadlevine gastritisasanimmunotherapyrelatedtoxicityinthetreatmentofendometrialcanceracasereport AT lauramchambers gastritisasanimmunotherapyrelatedtoxicityinthetreatmentofendometrialcanceracasereport AT christainagel gastritisasanimmunotherapyrelatedtoxicityinthetreatmentofendometrialcanceracasereport |